日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers.

利用新型验证的组织生物标志物增强局部前列腺癌的风险分层模型

Olah Csilla, Mairinger Fabian, Wessolly Michael, Joniau Steven, Spahn Martin, Kruithof-de Julio Marianna, Hadaschik Boris, Soós Aron, Nyirády Péter, Győrffy Balázs, Reis Henning, Szarvas Tibor

Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer

Nectin-4在肌层浸润性膀胱癌中的空间分布和亚型特异性表达模式

Olah, Csilla; Sichward, Lara; Hadaschik, Boris; Darr, Christopher; Grünwald, Viktor; Krafft, Ulrich; Grünwald, Barbara T; Mahmoud, Osama; Al-Nader, Mulham; Nyirady, Peter; Reis, Henning; Szarvas, Tibor

Immunohistochemistry-based molecular subtypes of urothelial carcinoma derive different survival benefit from platinum chemotherapy

基于免疫组织化学的尿路上皮癌分子亚型从铂类化疗中获得的生存获益各不相同。

Olah, Csilla; Shmorhun, Oleksandr; Klamminger, Gilbert Georg; Rawitzer, Josefine; Sichward, Lara; Hadaschik, Boris; Al-Nader, Mulham; Krafft, Ulrich; Niedworok, Christian; Váradi, Melinda; Nyirady, Peter; Kiss, Andras; Szekely, Eszter; Reis, Henning; Szarvas, Tibor

Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study

免疫检查点抑制剂治疗晚期尿路上皮癌在真实临床实践中的疗效:一项多中心回顾性研究的结果

Váradi, Melinda; Horváth, Orsolya; Módos, Orsolya; Fazekas, Tamás; Grunewald, Camilla M; Niegisch, Günter; Krafft, Ulrich; Grünwald, Viktor; Hadaschik, Boris; Olah, Csilla; Maráz, Anikó; Furka, Andrea; Szűcs, Miklós; Nyirády, Péter; Szarvas, Tibor

Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens

优化肌层浸润性膀胱癌共识分子亚型的鉴定:基于FFPE标本的两种测序方法和基因集的比较

Koll, Florestan J; Döring, Claudia; Olah, Csilla; Szarvas, Tibor; Köllermann, Jens; Hoeh, Benedikt; Chun, Felix K-H; Reis, Henning; Wild, Peter J

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas

临床测序在脐尿管癌和原发性膀胱腺癌中发现了高比例的潜在可干预改变。

Varadi, Melinda; Nagy, Nikolett; Reis, Henning; Hadaschik, Boris; Niedworok, Christian; Modos, Orsolya; Szendroi, Attila; Ablat, Jason; Black, Peter C; Keresztes, David; Csizmarik, Anita; Olah, Csilla; Gaisa, Nadine T; Kiss, Andras; Timar, Jozsef; Toth, Erika; Csernak, Erzsebet; Gerstner, Arpad; Mittal, Vinay; Karkampouna, Sofia; Kruithof de Julio, Marianna; Gyorffy, Balazs; Bedics, Gabor; Rink, Michael; Fisch, Margit; Nyirady, Peter; Szarvas, Tibor

Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer

分子亚型和APOBEC3G对尿路上皮膀胱癌辅助化疗的预测价值

Olah, Csilla; Reis, Henning; Hoffmann, Michèle J; Mairinger, Fabian; Ting, Saskia; Hadaschik, Boris; Krafft, Ulrich; Grünwald, Viktor; Nyirady, Peter; Varadi, Melinda; Győrffy, Balázs; Kiss, Andras; Szekely, Eszter; Sjödahl, Gottfrid; Szarvas, Tibor

MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients.

MMP-7 血清和组织水平与铂类药物治疗的膀胱癌患者的生存率低相关

Szarvas Tibor, Hoffmann Michèle J, Olah Csilla, Szekely Eszter, Kiss Andras, Hess Jochen, Tschirdewahn Stephan, Hadaschik Boris, Grotheer Vera, Nyirady Peter, Csizmarik Anita, Varadi Melinda, Reis Henning

Neoadjuvant cisplatin-based chemotherapy in "primary" and "secondary" muscle-invasive bladder cancer-is it a surrogate for molecular subtypes?

新辅助顺铂化疗在“原发性”和“继发性”肌层浸润性膀胱癌中的应用——能否作为分子亚型的替代指标?

Szarvas, Tibor; Olah, Csilla; Reis, Henning